Shaline Rao, MD
Advanced Heart Failure and Transplant Cardiology · Washington, DCNPI 1174724827
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $85,438 of the $120,004 with a category attached, or 71.2%. Boehringer Ingelheim accounts for 60.8% of it on its own, with 31 other manufacturers making up the rest.
Across 227 payments — averaging $528.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$73K
- Alnylam Pharmaceuticals Inc.$17K
- Novo Nordisk$6K
- Pharmacosmos Therapeutics Inc.$4K
- Eli Lilly$4K
- Lilly USA, LLC$3K
- plus $13K from 26 others
Across 4 payments — averaging $18,573 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$74K
What the payments were for
- Consulting fees$24,55120%
- Speaking & faculty fees$85,43871%
- Travel & lodging$4,1193%
- Food & beverage$5,8805%
- Education$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 85 | $72,911 |
| Alnylam Pharmaceuticals Inc. | 27 | $16,794 |
| Novo Nordisk | 3 | $6,239 |
| Pharmacosmos Therapeutics Inc. | 4 | $3,785 |
| Eli Lilly | 1 | $3,520 |
| Lilly USA, LLC | 5 | $3,300 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $2,972 |
| Abbott | 16 | $2,518 |
| Akcea Therapeutics, Inc. | 2 | $2,292 |
| Medtronic | 3 | $1,509 |
| Vifor (international) Ltd. | 2 | $1,042 |
| AstraZeneca | 5 | $1,007 |
| Pfizer | 13 | $751 |
| Novartis | 15 | $225 |
| Cvrx, Inc. | 2 | $200 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $136 |
| Merck | 7 | $114 |
| Daxor Corporation | 1 | $102 |
| E.r. Squibb & Sons, L.L.C. | 4 | $96 |
| Vifor Pharma, Inc. | 4 | $74 |
| Johnson & Johnson | 3 | $67 |
| Bridgebio Pharma, Inc. | 3 | $58 |
| Amgen | 3 | $53 |
| Scpharmaceuticals Inc. | 2 | $50 |
| Actelion Pharmaceuticals US, Inc. | 2 | $43 |
| Endotronix, Inc. | 1 | $36 |
| Impulse Dynamics (USA) Inc. | 1 | $25 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Bayer | 1 | $20 |
| Sensible Medical Innovations Inc | 1 | $16 |
| Lexicon Pharmaceuticals, Inc. | 1 | $15 |
| Gilead | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$19,780
- AMVUTTRA$15,002
- Monoferric$3,737
- CARDIOMEMS$1,148
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$652
- VYNDAMAX$520
- CardioMEMS HF System$330
- Barostim Neo System$189
- MitraClip$140
- BVA-100$102
How this compares
Too few advanced heart failure and transplant cardiology providers in District of Columbiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 74 | $76,495 |
| EliquisApixaban | 20 | $30,277 |
| Metoprolol Succinate | 56 | $981 |
| Torsemide | 20 | $431 |
| Atorvastatin Calcium | 34 | $304 |
| Furosemide | 27 | $158 |
| Spironolactone | 15 | $149 |
| Rosuvastatin Calcium | 11 | $138 |
| Carvedilol | 17 | $102 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $225 | $76,49574 claims |
| PfizerEliquis | $751 | $30,27720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in District of Columbiaon file to place this against a meaningful peer group, so we don't.
Other advanced heart failure and transplant cardiology in Washington
- Gurusher PanjrathWashington$426K
- Mrinalini KrishnanWashington$111K
- Farooq SheikhWashington$107K
- Tania VoraWashington$15K
- Samer NajjarWashington$12K
- Mark HofmeyerWashington$10K
- Ul WeenaWashington$4K
- Phillip LamWashington$4K
- Ahmed KhanWashington$957
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.